Generation of a broadly reactive influenza H1 antigen using a consensus HA sequence

Ping, Xianqiang; Hu, Weibin; Xiong, Rui; Zhang, Xi; Teng, Zheng; Ma, Ding; Li, Li; Chang, Chong E.; Xu, Ke

doi:10.1016/j.vaccine.2018.06.048

Cited by 8 publications

(8 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our data show that the pV-S_con group suppressed the shedding and replication of heterologous IBV strain M41 as efficiently as its homologous vaccine H120 (Figure 7). In line with our results, vaccines based on the consensus sequence of the HIV-1 envelope and influenza virus hemagglutinin and neuraminidase showed protective capability against heterologous strains [15][16][17][18][19]. Our study only used the IBV GI-1 strain in the virus challenge, however, more strains in different genotypes should be tested in the future.…”

Section: Discussionsupporting

confidence: 86%

“…The resulting sequence consists of a nucleotide or amino acid that is most commonly used at each site, reducing the genetic distances to all original strains [12][13][14][15][16]. Previous studies have demonstrated that consensus-sequence-based vaccines elicit broader immune responses in both human immunodeficiency virus-1 (HIV-1) and influenza viruses compared with vaccines using naturally occurring sequences [15,[17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Design and Characterization of a DNA Vaccine Based on Spike with Consensus Nucleotide Sequence against Infectious Bronchitis Virus

et al. 2021

View full text Add to dashboard Cite

Avian coronavirus infectious bronchitis virus (IBV) causes severe economic losses in the poultry industry, but its control is hampered by the continuous emergence of new genotypes and the lack of cross-protection among different IBV genotypes. We designed a new immunogen based on a spike with the consensus nucleotide sequence (S_con) that may overcome the extraordinary genetic diversity of IBV. S_con was cloned into a pVAX1 vector to form a new IBV DNA vaccine, pV-S_con. pV-S_con could be correctly expressed in HD11 cells with corresponding post-translational modification, and induced a neutralizing antibody response to the Vero-cell-adapted IBV strain Beaudette (p65) in mice. To further evaluate its immunogenicity, specific-pathogen-free (SPF) chickens were immunized with the pV-S_con plasmid and compared with the control pVAX1 vector and the H120 vaccine. Detection of IBV-specific antibodies and cell cytokines (IL-4 and IFN-γ) indicated that vaccination with pV-S_con efficiently induced both humoral and cellular immune responses. After challenge with the heterologous strain M41, virus shedding and virus loading in tissues was significantly reduced both by pV-S_con and its homologous vaccine H120. Thus, pV-S_con is a promising vaccine candidate for IBV, and the consensus approach is an appealing method for vaccine design in viruses with high variability.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Design and Characterization of a DNA Vaccine Based on Spike with Consensus Nucleotide Sequence against Infectious Bronchitis Virus

et al. 2021

View full text Add to dashboard Cite

show abstract

“…1c, subtype-specific). Another approach to generate broader subtype-specific immune responses is to design 'consensus' sequences using computational algorithms [51][52][53][54][55][56] . One such antigen, termed 'computationally optimized, broadly reactive antigen' (COBRA), induces some cross-reactive antibodies within subtypes, such as H1, H3 or H5, in preclinical studies 51,53,55 .…”

Section: Nucleoproteinmentioning

confidence: 99%

Next-generation influenza vaccines: opportunities and challenges

Wei

Crank

Shiver

et al. 2020

Nat Rev Drug Discov

220

203

View full text Add to dashboard Cite

Vaccination represents an efficient and cost-effective way to contain influenza epidemics and preserve public health. Since their introduction in the 1940s, seasonal influenza vaccines have saved countless lives and limited pandemic spread. Influenza viruses nonetheless continue to evolve through genetic mutation and escape from natural immunity, and vaccines must be updated yearly. The protective efficacy of the current licensed vaccines varies each year (Fig. 1a), depending on the antigenic match between circulating viruses and vaccine strains. The immune status of the host can also affect vaccine efficacy. For example, young and elderly individuals are more susceptible to the complications of influenza infection [1][2][3] .New influenza viruses have precipitated pandemics several times over the past 100 years, specifically in 1918, 1957, 1968 and 2009 (reF. 4 ). The threat of the reemergence of old pandemic viruses and the emergence of novel viruses with pandemic potential underscore the need for durable and broadly protective influenza vaccines. Advances in immunology and virology, together with information from structural biology and bioinformatics, are facilitating the development of novel vaccine approaches [5][6][7][8] . Of particular interest are human broadly neutralizing antibodies directed to conserved viral structures. These antibodies arise naturally and can also be elicited through immunization .Current licensed influenza vaccines contain either in activated or live attenuated influenza viruses. Most in activated vaccines consist of split viruses or subunit influenza antigens (Table 1). Split vaccines are produced by disrupting viral particles with chemicals or detergents Haemagglutinin (Ha). a homotrimeric glycoprotein found on the surface of influenza virus particles responsible for the recognition of the host target cell through the binding of sialic acid-containing receptors.

show abstract

“…In one particular effort, a broadly-reactive vaccine was created by engineering a consensus of 2656 HA H1N1 protein sequences into one protein, CH1, that bore conserved B and T cell epitopes. A PR8-CH1 influenza virus elicited broadly-protective immunity against heterologous H1N1 viruses [101]. Researchers also considered using the neuraminidase (NA) since it is a less rapidly-evolving protein and thus a good contributor for vaccine antigens.…”

Section: Improving the Humoral Immune Response To Lassa Vaccinesmentioning

confidence: 99%

Improving the Breadth of the Host’s Immune Response to Lassa Virus

et al. 2018

View full text Add to dashboard Cite

In 2017, the global Coalition for Epidemic Preparedness (CEPI) declared Lassa virus disease to be one of the world’s foremost biothreats. In January 2018, World Health Organization experts met to address the Lassa biothreat. It was commonly recognized that the diversity of Lassa virus (LASV) isolated from West African patient samples was far greater than that of the Ebola isolates from the West African epidemic of 2013–2016. Thus, vaccines produced against Lassa virus disease face the added challenge that they must be broadly-protective against a wide variety of LASV. In this review, we discuss what is known about the immune response to Lassa infection. We also discuss the approaches used to make broadly-protective influenza vaccines and how they could be applied to developing broad vaccine coverage against LASV disease. Recent advances in AIDS research are also potentially applicable to the design of broadly-protective medical countermeasures against LASV disease.

show abstract

Generation of a broadly reactive influenza H1 antigen using a consensus HA sequence

Cited by 8 publications

References 35 publications

Design and Characterization of a DNA Vaccine Based on Spike with Consensus Nucleotide Sequence against Infectious Bronchitis Virus

Design and Characterization of a DNA Vaccine Based on Spike with Consensus Nucleotide Sequence against Infectious Bronchitis Virus

Next-generation influenza vaccines: opportunities and challenges

Improving the Breadth of the Host’s Immune Response to Lassa Virus

Contact Info

Product

Resources

About